Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.59 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.59 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.59 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7088307 | 0.92 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027178 | 0.92 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027181 | 0.92 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4027184 | 0.92 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| Quinoline SCHEMBL27575381 | 0.88 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034289 | 0.84 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034297 | 0.84 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL4034294 | 0.84 | PDE4A (0.75) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL7449314 | 0.78 | PDE4A (0.73) | PDE4APDE4BPDE4CPDE4DCYP2C9 | |
| SCHEMBL6988514 | 0.78 | PDE4A (0.66) | PDE4APDE4BPDE4CPDE4DCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | disclosed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |